Tags Archive Navigation
icon
-
Media ReleaseNovartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
-
Media ReleaseSandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
-
StoryTreatments for blood cancers and serious blood disorders are advancing rapidly – Novartis is helping lead the way
-
Interior PageInnovation in CML at Novartis
-
Media ReleaseNovartis unveils results from global patient and physician survey disrupting the notion that CML is a solved disease
-
Media ReleaseNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
-
Interior PageASCO 2023
-
Landing PageASCO annual meeting
-
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
-
Media ReleaseNovartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
-
Media ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 14
- › Next page